Better Living Peptides
BLP RESEARCH HUBResearch. Regeneration. Results.

WEIGHT & METABOLIC RESEARCH

Tirzepatide

Studied for appetite control, blood-sugar regulation, and body composition, working through two gut-hormone pathways at once.

Tirzepatide activates two gut-hormone pathways together, GIP and GLP-1, the signals that tell the body it has eaten and help it handle the glucose from a meal. It is studied for appetite, glucose regulation, insulin sensitivity, and body-composition outcomes, and is an FDA-approved medication in its clinical formulations.

GIP / GLP-1 Dual AgonistWeight & MetabolicGlucose RegulationBody Composition

Why BLP features Tirzepatide

Included because it combines FDA-approved human evidence with a well-mapped dual-receptor mechanism and broad, consistent clinical and research use. It anchors the established end of the metabolic-research spectrum.

Mechanism

Activates GLP-1 receptors to reduce appetite and slow how fast the stomach empties, so meals stay satisfying longer.

Activates GIP receptors to support the insulin response and broader metabolic signaling.

Together these help regulate food intake, post-meal glucose handling, and energy balance.

WHAT THE RESEARCH MEASURED

Research findings

Findings describe study outcomes, not expected personal results.

Human research findings

  • The pivotal SURMOUNT-1 trial reported average weight loss of 20.9% at 72 weeks at the 15mg dose, and Tirzepatide outperformed Semaglutide (20.2% vs 13.7%) in the SURMOUNT-5 head-to-head trial.
  • Reported improved glycemic control and lower HbA1c.
  • Reported reduced appetite and caloric intake, with better insulin sensitivity and fasting glucose markers.
  • Reported improvements in waist circumference and triglycerides. GI side effects were most noticeable during dose escalation and often improved over time.

Mechanistic & supporting research

  • Dual-receptor mechanism established through incretin pharmacology.
  • GIP + GLP-1 co-agonism modeled as producing complementary appetite and insulin-sensitivity effects.

Regulatory status

Tirzepatide is FDA-approved in its clinical formulations. Material offered here is sold and offered strictly for laboratory and research use and is not a medicine.

Related research

RetatrutideCagrilintideTesamorelinEvidence FrameworkResearch Library